Tokyo, Japan, Nov 2, 2005 - (JCNN) - Sumitomo Chemical announced on November 1 that it and its subsidiary Dainippon Sumitomo Pharma have jointly filed suit against Pfizer in the Tokyo District Court on the same day.
In response to a preliminary injunction petition filed by Pfizer in October, the two companies seek a declaratory judgment that their right to manufacture and sell amoldipine besilate remains valid. Amoldipine besilate is a hypertension drug discovered by Pfizer.
Since 1991, Pfizer and Sumitomo Pharamceuticals, one of the two predecessor companies of Dainippon Sumitomo Pharma, have entered into a licensing agreement for amoldipine bestilate.
Sumitomo Pharmaceuticals has been marketing the agent under the trade name of Amoldin since then.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group